Physician profile
Raymond H Moncivaiz
NPI 1285214213
$818.23
in general payments reported to CMS, 2019-2025
12 companies · $52.48 in 2025
The $52.48 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.38 · 2023: $110 · 2024: $614 · 2025: $52.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $186.89 | 2023-2025 | Rybelsus |
| Abbvie INC. | $168.13 | 2024 | |
| Lilly USA, LLC | $129.14 | 2023-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $85.57 | 2024 | |
| Glaxosmithkline, LLC. | $77.78 | 2022-2024 | Shingrix, Trelegy Ellipta |
| Abiomed | $43.92 | 2024 | Impella |
| Shield Therapeutics INC | $33.75 | 2024 | |
| Dexcom, INC. | $23.66 | 2025 | Dexcom G6 Transmitter |
| Philips North America LLC | $21.93 | 2024 | (Ck6) Holter |
| Janssen Pharmaceuticals, INC | $18.53 | 2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $15.82 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Moncivaiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.